Summary A total of 161 previously untreated patients with FIGO stage III or IV epithelial ovarian cancer were randomised after surgery to receive six courses of either carboplatin 400 mg m2 alone (Arm A) or carboplatin 300mg m-2 with chlorambucil 10 mg day-' for 7 days (Arm B). The median progression free survival (PFS) was similar: arm A: 45 weeks; arm B: 61 weeks (P = 0.830). Multivariate Cox regression analysis showed that the extent of residual disease and performance status were the most important prognostic factors for PFS.
Fifty-two per cent of patients received dose escalations based on nadir blood counts, ahd 89% of all dose adjustments were made according to protocol. Failure to achieve a significant degree of leucopenia was associated with worse progression free survival (P<0.001). A total of 29.4% of patients fall into this category.
The median survival was similar in both arms, i.e. 75 weeks. It is unlikely that there is any major clinical advantage to adding chlorambucil to single agent carboplatin for the management of advanced ovarian cancer, but whether used in combination or a single agent, the dose of carboplatin should be sufficient to cause at least grade I leucopenia. This may best be achieved by determining the initial dose based on renal function, and then adjusting subsequent doses according to nadir blood counts.
For the past decade the treatment of advanced ovarian cancer has generally comprised maximal debulking surgery followed by combination chemotherapy. Cisplatin has been the most active single agent. At a dose of 100mgm-2 cisplatin every 3 or 4 weeks the clinical complete and partial response rates exceed 50% and the pathological complete remission rate is around 30% in patients who have received no prior chemotherapy or radiotherapy. Many clinicians judge the most effective treatment for the majority of patients to be a combination chemotherapy regimen using cisplatin at the maximally tolerated dose, usually 100 mg m-2 (Ozols, 1985) . A large randomised Italian study has shown a higher response rate for combination chemotherapy with cisplatin, adriamycin and cyclophosphamide compared with cisplatin alone, although no survival differences were observed, perhaps because of cross-over between the treatment arms (GICOG, 1987) .
Cisplatin is associated with considerable toxicity. This has led some workers to question the practice of treating the majority of women (especially those with bulk residual disease) with cisplatin, since no overall survival benefit has been demonstrated when compared with single agent chlorambucil (Williams et al., 1985) . However, these analyses are complicated by the use of cisplatin as second-line therapy at the time of relapse (Dembo, 1986) .
The platinum analogue carboplatin appears to have equivalent anti-tumour activity to cisplatin, but is better tolerated. Renal and neurological toxicity have not been associated with carboplatin at standard dose, although haematological toxicity, particularly thrombocytopenia is more marked than with cisplatin (Evans et al., 1983) . A recent study compared carboplatin at 400mgm-2 (with provision for dose escalation according to the blood count on the day of treatment) with cisplatin 100 mg m-2, both given monthly (Mangioni et al., 1989) . No clinically important difference in progression-free or overall survival was seen in the two arms, but in the carboplatin arm there was less nephrotoxicity and more, but rarely troublesome, myelosuppression.
Several studies have suggested that a dose-response relationship exists for cisplatin (Ozols et al., 1985; Hryniuk, 1987) , and the same is likely to apply to carboplatin. If carboplatin is to be used in combination with other myelosuppressive agents, a reduction in dose is inevitably necessary, and the impact of this on overall efficacy is uncertain (McGuire & Abeloff, 1989) . A Dutch study comparing a four drug combination including carboplatin with the same drugs and cisplatin found little difference in response (Ten Bokkel Huinink et al., 1987) and a collaborative study of the SouthWestern Oncology Group (SWOG) likewise showed similar efficacy for carboplatin and cisplatin when combined with cyclophosphamide (Alberts et al., 1989) . However, Edmonson and colleagues showed recently that carboplatin with cyclophosphamide gave substantially inferior progression free survival than cisplatin with cyclophosphamide, but in this study only 150 mg m2 carboplatin could be given with the dose of 1 g m-2 of cyclophosphamide (Edmonson et al., 1989) .
We chose to combine carboplatin with chlorambucil. There is no evidence that any particular alkylating agent is more effective than any other in ovarian cancer (Young et al., 1974) . Chlorambucil has been extensively tested in ovarian cancer giving an overall response rate of 50% (Ozols & Young, 1984) and the same overall survival when compared prospectively with cisplatin (Williams et al., 1984) . It has the advantage that it is well tolerated, does not cause alopecia nor the gastrointestinal or bladder toxicity associated with cyclophosphamide. Our pilot study has shown that carboplatin 300 mg m-could safely be combined with chlorambucil 10 mg daily for 7 days (Harding et al., 1988 day intervals providing that the total white count on the day of treatment was at least 3.0 x 1091-, and platelets at least 100 x 109 1-. If these values were not reached, treatment was delayed for 1 week. If treatment was postponed for longer than 2 weeks because of continuous myelosuppression (i.e. more than 6 weeks between cycles) protocol therapy was stopped.
The full blood count was measured at weekly intervals and the dose for second and subsequent courses modified according to the nadir count in the preceding cycle. Treatment delay alone did not lead to alteration in dose. If the nadir white blood count was > 4 x 109 1-' and platelets > 100 x 109 1`the dose of carboplatin was increased to 500 mg m-2 in Arm A and 375 mg m-2 in Arm B, but the dose of chlorambucil was unchanged. This dose was used for all further courses unless the nadir white cell count after dose escalation fell to <1 x 109 1-or platelets <25 x 1091ẁ hen the carboplatin dose reverted to 400 mg m-2 and 300 mg m-2 respectively. If, following treatment with 400 mg m 2 carboplatin in Arm A or 300 mg m 2 carboplatin and 7 days of chlorambucil in Arm B, the nadir white cell count was <1 x I09 lI-I or the platelet count was < 25 x 109 l1-'the dose of carboplatin was reduced to 300 mg m-2 in Arm A, and in Arm B the dose of carboplatin was reduced to 225 mg m2 and chlorambucil to 10mg daily for 5 days. If the nadir after dose reduction was still low (white cell count <1 x 109 1-or platelets <25 x 1091-i) the dose of carboplatin was further reduced to 225 mg m-2 in the single agent arm and in the combination arm chlorambucil was stopped and carboplatin given at a dose of 225 mgm2. If a dose reduction had been necessary no subsequent increase in dose was allowed.
Treatment and toxicity and response assessment All patients had a chest radiograph, serum biochemical screen and full blood count, creatinine clearance, an abdominal and pelvic ultrasound scan and documentation of the dimensions of tumour masses prior to starting chemotherapy. Patients were evaluated by physical and gynaecological examination each month, when renal and hepatic function, performance status and toxicity were also recorded. Tumour response was assessed by clinical examination, abdominal and pelvic ultrasound and appropriate radiographs after three and six cycles of treatment. Toxicity was recorded according to the recommendations of WHO (WHO Handbook, 1979) .
Protocol therapy consisted of six cycles of the allocated treatment. Patients who developed clinical evidence of progressive disease stopped protocol treatment. Rising CA125 alone -'biochemical progression' was not considered sufficient for the patient to discontinue treatment. Those patients in whom the treatment interval exceeded 6 weeks (or 8 weeks if interval debulking surgery was performed) stopped protocol treatment.
Clinical response was assessed using standard criteria for complete and partial response, stable disease and progression (WHO Handbook, 1979) . 'Pathological' response data were obtained in those patients undergoing post-chemotherapy surgery, but this was not obligatory. An analysis of progression free survival in terms of average haematological toxicity experienced by the patient was conducted. Actual nadir WBC and platelet counts for each cycle were 'used to calculate the overall average nadir values for each patient. In this analysis patients were first stratified according to the number of courses of chemotherapy they received; the intention of this was to remove any possible confusion of the comparison as a result of patients in the different haematological toxicity categories having received a different number of courses of chemotherapy and therefore having had different opportunites to achieve adequate myelosuppression. The analysis was then repeated adjusting for the two previously identified major prognostic-factors (performance status and extent of residual disease) by including these as co-variates in the proportional hazards model (Table V) .
Patients whose average level of leucopenia did not exceed grade 0 had a worse outcome than those achieving higher grades (see Figure 3) . A similar observation is seen with thrombocytopenia, but this does not achieve statistical significance. When leucopenia and thrombocytopenia are considered together in a multivariate analysis, the effect of thrombocytopenia is diminished, suggesting that leucopenia is the more important prognostic factor. Almost identical results are obtained if analysis is restricted to those patients who received at least three cycles.
The median disease-free survival in those with a clinical complete remission, i.e. patients with clinically measurable disease at the start of treatment, was 74 weeks (95% C.I. aInformation on blood counts is only used for patients who had these recorded: on all courses, for patients receiving < four courses; on at least four courses, for patients receiving > five courses. bThe P-value obtained after stratifying for the number of cycles received. cThis P-value is obtained after stratifying for the number of cycles received and including performance status and extent of residual disease in the proportional hazards model.
35-101 weeks)
. The median disease-free survival in the seven patients with pathological complete remission was 98 weeks.
The overall survival in the two groups was similar (P = 0.552) with the same median survival at 75 weeks as shown in Figure 4 . Again the wide 95% confidence intervals of 0.77 to 1.64 for relative death rate indicate that quite large real survival differences between the treatment arms cannot be excluded. The amount of residual disease present before chemotherapy again influenced the long-term outcome as shown in Figure 5 . Since randomised studies indicate that, at least in terms of response, the combination of an alkylating agent with cisplatin is superior to cisplatin alone (GICOG, 1987) , a key issue for the future use of carboplatin will be its activity when combined with an alkylating agent. Our own pilot sudy had shown that a combination of carboplatin 300 mgm-' with ch-lorambucil 10 mg d x 7 days was well tolerated, and although dose reduction was sometimes required, dose escalation was possible in some patients (Harding et al., 1988). In the randomised study reported here the dose for each cycle was based on the nadir blood count in the preceding cycle and both escalation and reduction were possible. Pro We have observed a clear association between leucopenia and progression-free survival, and this is independent of other prognostic factors, i.e. performance status and extent of residual disease. While it is conceivable that patients prone to leucopenia have an inherently better prognosis, intuitively it is logical to suggest that interpatient variations in drug handling may affect outcome. A recent analysis of 767 patients treated with carboplatin for ovarian cancer has confirmed the relationship between tumour response and individual patient pharmacokinetics, i.e. area under the curve (Egorin et al., 1991) . For these reasons it would be appropriate in patients receiving carboplatin alone or in combination to adjust the dose as necessary to achieve adequate myelosuppression (at least Grade 1) with each course of treatment. Adjustments of dose based on the criteria used in this study are simple to operate and easy to apply. Several other formulae are available for carboplatin alone (Egorin et al., 1985; Fish et al., 1987) or in combination (Calvert et al., 1989; Belani et al., 1989) . We suggest that the individual variation in carboplatin handling can best be accommodated by determining the initial dose of carboplatin used alone or in combination on the basis of renal function (Calvert et al., 1989) and adjusting subsequent doses according to the nadir blood count.
One other study in ovarian cancer has shown that myelosuppression during chemotherapy confers an improved survival probability (GG.COSA, 1986) . In that study which compared combination vs sequential therapy with chlorambucil and cisplatin, myelosuppression (defined as white cell count <2.5 x 109 -' and/or platelets <100 x 109 1-) acted as an independent variable in the Cox multivariate analysis with a P value of <0.001.
The dose of carboplatin used in either arm of our study is in line with that used in the other quoted studies. Mangioni and colleagues incorporated provision for dose escalation based on the blood count on the day of treatment, to a maximum of 500 mg m-2 carboplatin by 50 mg m-2 steps (Mangioni et al., 1989) . In that study 38% patients had a dose escalation and 32% reduction. In our study, where the number of dose adjustments was similar in both arms and where the nadir blood count was used to guide the dose, 50% patients had at least one dose escalation and 25% a dose reduction.
In conclusion, we have compared carboplatin alone with a combination of carboplatin and chlorambucil in a randomised study in patients with Stage III and IV ovarian cancer. We found no statistically significant difference in the progression-free survival or overall survival between the two treatments. It therefore seems unlikely that there is any major advantage (i.e. median survival difference of 30% or more) to adding an alkylating agent, at least chlorambucil, to single agent carboplatin for the management of this disease. The amount of residual disease at the start of chemotherapy and the performance status were the most important predictors for progression-free survival. Although the median overall survival seen in both arms in this study of 75 weeks, is less than that which can be achieved with cisplatin-based combination therapy, proper comparisons can only be made on prospective randomised studies with long-term follow-up.
